Dunvegan Associates’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Dunvegan Associates’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$75K	Sell	1,468 -178	-11%	-$9.07K	0.09%	76
2015 Q3	$77K	Hold	1,646	–	–	0.09%	75
2015 Q2	$103K	Hold	1,646	–	–	0.11%	67
2015 Q1	$102K	Hold	1,646	–	–	0.09%	85
2014 Q4	$89K	Sell	1,646 -328	-17%	-$17.9K	0.08%	82
2014 Q3	$105K	Hold	1,974	–	–	0.09%	74
2014 Q2	$102K	Hold	1,974	–	–	0.09%	77
2014 Q1	$92K	Buy	+1,974	New	+$93.2K	0.08%	78

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

KHLMVGHM

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet Tel Aviv, Israel $2.44B AUM 24.95% 1-Year Est. Return

Dunvegan Associates's XPH Position: Q4 2015 in Review

Dunvegan Associates reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 11% in Q4 2015, selling an estimated $9.07K and leaving 1,468 shares worth $75K. The position accounts for 0.09% of the portfolio, ranked #76.

Dunvegan Associates first reported a position in XPH in Q1 2014 and has held it in 8 quarters since. The position peaked at $105K in Q3 2014. 76 funds tracked by Wall St. Rank hold XPH as of Q4 2015.

Dunvegan Associates held 1,468 shares of State Street SPDR S&P Pharmaceuticals ETF worth $75K as of Q4 2015.
Dunvegan Associates sold 178 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2015, an estimated $9.07K.
State Street SPDR S&P Pharmaceuticals ETF made up 0.09% of Dunvegan Associates's portfolio in Q4 2015, its #76 holding.
Dunvegan Associates first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2014 and has held it in 8 quarters since.
Dunvegan Associates's State Street SPDR S&P Pharmaceuticals ETF position peaked at $105K in Q3 2014.
76 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.